Therapeutic Effects of a NEDD8-Activating Enzyme (NAE) Inhibitor, Pevonedistat, on Sclerodermatous Graft Versus Host Disease in Mice

• Published in: Biology of blood and marrow transplantation Vol. 23; no. 1; pp. 30 - 37
• Main Authors: Pai, Chien-Chun Steven, Khuat, Lam T, Chen, Mingyi, Murphy, William J, Abedi, Mehrdad
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2017
• Subjects: Animals; Antigen-Presenting Cells - drug effects; Antigen-Presenting Cells - immunology; Cyclopentanes - therapeutic use; Enzyme Inhibitors - therapeutic use; Graft vs Host Disease - drug therapy; Graft vs Host Disease - pathology; Graft vs Tumor Effect - immunology; Graft-versus-tumor effect; Hematology, Oncology and Palliative Medicine; Hematopoietic Stem Cell Transplantation - adverse effects; Lymphoma, B-Cell - therapy; Mice; Pevonedistat; Pyrimidines - therapeutic use; Scleroderma, Systemic - drug therapy; Scleroderma, Systemic - etiology; Sclerodermatous graft-versus-host disease; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Time Factors; Transplantation, Homologous - adverse effects; Ubiquitin-Activating Enzymes - antagonists & inhibitors; Sclerodermatous graft-versus-host disease; Graft-versus-tumor effect; Pevonedistat
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2016.10.022

Highlights - Pevonedistat treatment at the onset stage strongly inhibits sclerodermatous GVHD. - Pevonedistat inhibits antigen-presenting cells while having minimal effects on T cells. - Pevonedistat maintains graft-versus-tumor effects.